Topical Remedies for Chronic Venous Disease Management. Composition as the Basis of Effectiveness

Porembskaya O.Ya.

doi:https://doi.org/10.17116/flebo202014041322

Close metadata

Recommended articles:

Efficiency of Local Therapy in Patients with Venous Symptoms. Journal of Venous Disorders. 2024;(4):302-307

Evaluation of whole blood immunoreactivity. Pirogov Russian Journal of Surgery. 2024;(12-2):122-126

Correction of the effect of direct oral and parenteral anticoagulants in hemorrhagic stroke. Burdenko's Journal of Neurosurgery. 2025;(1):109-115

Resolution of the Council of Experts on the Treatment of Radiculopathy “New approaches to the treatment of back pain”. Russian Journal of Pain. 2025;(1):84-90

Pharmacokinetic and pharmacodynamic aspects of the anti-edematous agent escin lysinate. Russian Journal of Anesthesiology and Reanimatology. 2025;(4):81-86

Escin lysinate effectiveness for edema correction in various zones. Russian Journal of Anesthesiology and Reanimatology. 2025;(5):120-125

Abstract:

Topical agents are widely used in the treatment of chronic venous diseases (CVD) and acute thrombophlebitis. However, various physicians are skeptical about the effectiveness of such medication. They believe that the effects of topical agents are based on massage manipulation rather pharmacological activity per se. Massage effect together with skin cooling caused by volatile matter evaporation can only partially explain symptoms improvement induced by transdermal system application. Significance of these effects is confirmed by short-term reduction of some specific venous symptoms following placebo. Effectiveness of heparin and escin-based remedies is determined by specific pharmacological properties with anti-inflammatory and decongestant effects. This review is devoted to transdermal forms of heparin and escin in combination with essential phospholipids. The last ones form liposomes, promote penetration of heparin and escin into deeper skin layers and potentiate their activity. These remedies reduce severity of specific venous symptoms (heaviness in legs, fatigue, edema, pain, convulsions) in patients with chronic venous diseases and relieve acute inflammation in case of acute thrombophlebitis.

Keywords:

thrombophebitis

venous disease

topical treatment

heparin

escin

essential phospholipids

Authors:

Porembskaya O.Ya.

Mechnikov North-Western State Medical University;
Institute of Experimental Medicine

SPIN RSCI: 9775-1057
Scopus AuthorID: 56743328700
ORCID: 0000-0003-3537-7409

Received:

07.09.2020

Accepted:

23.09.2020

Close metadata

References:

Chowdhury M. Dermatological pharmacology: topical agents. Medicine (Baltimore). 2013;41(6):327-329. https://doi.org/10.1016/j.mpmed.2013.04.012
Stoyko YuM, Kirienko AI, Zatevakhin II, Pokrovsky AV, Karpenko AA, Zolotukhin IA, Sapelkin SV, Ilyukhin EA, Gavrilov SG, Porembskaya OYa, Borsuk DA, Seliverstov EI, Alukhanyan OA, Andriyashkin AV, Andriyashkin VV, Barinov VE, Belentsov SM, Bogdanets LI, Bredikhin RA, Bukina OV, Burleva EP, Vakhitov MSh, Vinogradov LA, Volkov AYu, Golovanova OV, Guzhkov ON, Ivanov EV, Katelnitskaya OV, Katorkin SE, Kletskin AE, Koshevoy AP, Krylov AYu, Kudykin MN, Kuzovlev SP, Laberko LA, Larin SI, Lishov DE, Lobastov KV, Mazayshvili KV, Markin SM, Parikov MA, Pelevin AV, Potapov MP, Pryadko SI, Rapovka VG, Sabelnikov VV, Slavin DA, Sokolov AL, Soldatsky EYu, Sonkin IN, Starodubtsev VN, Subbotin YuG, Suchkov IA, Sushkov SA, Tolstikhin VYu, Fokin AA, Khitaryan AG, Khodkevich MB, Khorev NG, Tsukanov YuT, Chabbarov RG, Chernookov AN, Chechetka DYu, Shevela AI, Shimanko AI, Shonov OA, Yashkin MN, Bogachev VYu, Bubnova NA, Dibirov MD, Zhukov BN, Kalinin RE, Katelnitsky II, Plechev VV, Shaydakov EV, Shulutko AM. Diagnostics and Treatment of Chronic Venous Disease: Guidelines of Russian Phlebological Association. Flebologiya. 2018;12(3):146-240. (In Russ.). https://doi.org/10.17116/flebo20187031146
Belcaro G, Nicolaides A, Geroulakos G, Cesarone M, Incandela L, De Sanctis M. Essaven Gel. Angiology. 2001;52(3 suppl):1-4. https://doi.org/10.1177/0003319701052003s02
Incandela L, Belcaro G, Cesarone M, De Sanctis M, Griffin M. Microangiopathy and Venous Ulceration: Topical Treatment with Essaven Gel. Angiology. 2001;52(3 suppl):17-21. https://doi.org/10.1177/0003319701052003s05
De Sanctis M, Cesarone M, Incandela L, Belcaro G, Griffin M. Treatment of Superficial Vein Thrombosis with Standardized Application of Essaven Gel. Angiology. 2001;52(3 suppl):57-62. https://doi.org/10.1177/0003319701052003s11
Vaghasiya K, Sharma A, Kumar K, Ray E, Adlakha S, Katare OP, Hota SK, Verma RK. Heparin-Encapsulated Metered-Dose Topical “Nano-Spray Gel” Liposomal Formulation Ensures Rapid On-Site Management of Frostbite Injury by Inflammatory Cytokines Scavenging. ACS Biomater Sci Eng. 2019;5(12):6617-6631. https://doi.org/10.1021/acsbiomaterials.9b01486
Camprubí-Rimblas M, Tantinyà N, Bringué J, Guillamat-Prats R, Artigas A. Anticoagulant therapy in acute respiratory distress syndrome. Ann Transl Med. 2018;6(2):36-36. https://doi.org/10.21037/atm.2018.01.08
Casu B, Naggi A, Torri G. Re-visiting the structure of heparin. Carbohydr Res. 2015;403:60-68. https://doi.org/10.1016/j.carres.2014.06.023
Lindahl U, Li J. Heparin — An old drug with multiple potential targets in Covid‐19 therapy. Journal of Thrombosis and Haemostasis. 2020;18(9): 2422-2424. https://doi.org/10.1111/jth.14898
Lehman C, Frank E. Laboratory Monitoring of Heparin Therapy: Partial Thromboplastin Time or Anti-Xa Assay? Lab Med. 2009;40(1):47-51. https://doi.org/10.1309/lm9njgw2ziolphy6
Vecchio C, Frisinghelli A. Topically Applied Heparins for the Treatment of Vascular Disorders. Clin Drug Investig. 2008;28(10):603-614.
Katakkar S. Use of Heparin as a Topical Antithrombotic and Anti-inflammatory Agent. JNCI Journal of the National Cancer Institute. 1993;85(22): 1865-1866. https://doi.org/10.1093/jnci/85.22.1865
Betz G, Nowbakht P, Imboden R, Imanidis G. Heparin penetration into and permeation through human skin from aqueous and liposomal formulations in vitro. Int J Pharm. 2001;228(1-2):147-159. https://doi.org/10.1016/s0378-5173(01)00832-8
Artmann C, Röding J, Ghyczy M, Pratzel HG. Liposomes from soya phospholipids as percutaneous drug carriers. 2nd communication: quantitative in vivo investigations with radioactively labelled liposomes. Arzneimittelforschung. 1990;40(12):1365-1368.
Villardell M, Sabat D, Arnaiz J, Bleda MJ, Castel JM, Laporte JR, Vallvé C. Topical heparin for the treatment of acute superficial phlebitis secondary to indwelling intravenous catheter. Eur J Clin Pharmacol. 1999;54(12):917-921. https://doi.org/10.1007/s002280050575
Humphries D, Wong G, Friend D, Gurish MF, Qiu WT, Huang C, Sharpe AH, Stevens RL. Heparin is essential for the storage of specific granule proteases in mast cells. Nature. 1999;400(6746):769-772. https://doi.org/10.1038/23481
Page C. Heparin and Related Drugs: Beyond Anticoagulant Activity. ISRN Pharmacol. 2013;2013:1-13. https://doi.org/10.1155/2013/910743
Gallelli L. Escin: a review of its anti-edematous, anti-inflammatory, and venotonic properties. Drug Des Devel Ther. 2019;13:3425-3437. https://doi.org/10.2147/DDDT.S207720
Lang W. Studies on the percutaneous absorption of3H-Aescin in Pigs. Research in Experimental Medicine. 1977;169(3):175-187. https://doi.org/10.1007/bf01852057
Zhao S, Xu S, Cheng J, Cao XL, Zhang Y, Zhou WP, Huang YJ, Wang J, Hu XM. Anti-inflammatory effect of external use of escin on cutaneous inflammation: possible involvement of glucocorticoids receptor. Chin J Nat Med. 2018;16(2):105-112. https://doi.org/10.1016/s1875-5364(18)30036-0
Facino R, Carini M, Stefani R, Aldini G, Saibene L. Anti-Elastase and Anti-Hyaluronidase Activities of Saponins and Sapogenins fromHedera helix, Aesculus hippocastanum, and Ruscus aculeatus: Factors Contributing to their Efficacy in the Treatment of Venous Insufficiency. Arch Pharm (Weinheim). 1995;328(10):720-724. https://doi.org/10.1002/ardp.19953281006
Montopoli M, Froldi G, Comelli M, Prosdocimi M, Caparrotta L. Aescin Protection of Human Vascular Endothelial Cells Exposed to Cobalt Chloride Mimicked Hypoxia and Inflammatory Stimuli. Planta Med. 2007;73(3): 285-288. https://doi.org/10.1055/s-2007-967118
Pabst H, Segesser B, Bulitta M, Wetzel D, Bertram S. Efficacy and Tolerability of Escin/Diethylamine Salicylate Combination Gels in Patients with Blunt Injuries of the Extremities. Int J Sports Med. 2001;22(6):430-436. https://doi.org/10.1055/s-2001-16251
Wetzel D. Escin/diethylammonium salicylate/heparin combination gels for the topical treatment of acute impact injuries: a randomised, double blind, placebo controlled, multicentre study. Br J Sports Med. 2002;36(3):183-188. https://doi.org/10.1136/bjsm.36.3.183
Siebert U, Brach M, Sroczynski G, Berla K. Efficacy, routine effectiveness, and safety of horsechestnut seed extract in the treatment of chronic venous insufficiency. A meta-analysis of randomized controlled trials and large observational studies. Int Angiol. 2002;21(4):305-315.
Savelyeva MI, Sychev DA. Potential of the Transdermal Drug Delivery Systems for the Topical Treatment of Chronic Venous Diseases. Flebologiya. 2018;12(1):40-49. (In Russ.). https://doi.org/10.17116/flebo201812140-49
Lobastov KV. Impact of microcirculatory disorders on the symptoms of chronic venous disease and their pharmacological correction. Flebologiya. 2020;14(1):30-39. (In Russ.). https://doi.org/10.17116/flebo20201401130
Sukovatykh BS, Sereditsky AV, Sukovatykh MB, Rodionov OA. Efficacy of Detragel un treatment of varicothrombophlebitis in elderly and aged patients. Angiology and Vascular Surgery. 2020;26(1):69-79. (In Russ.). https://doi.org/10.33529/ANGI02020108
Virgini-Magalhães C, Porto C, Fernandes F, Dorigo D, Bottino D, Bouskela E. Use of microcirculatory parameters to evaluate chronic venous insufficiency. J Vasc Surg. 2006;43(5):1037-1044. https://doi.org/10.1016/j.jvs.2005.12.065
Howlader M, Smith P. Microangiopathy in chronic venous insufficiency: Quantitative assessment by capillary microscopy. European Journal of Vascular and Endovascular Surgery. 2003;26(3):325-331. https://doi.org/10.1053/ejvs.2002.1976
Azizov GA, Kozlov VI. Chronic venous insufficincy of lower limbs: microcirculatory features. Vestnik Rossijskogo universiteta druzhby narodov. Seriya: Meditsina. 2003;3:117-120. (In Russ.).
Senra Barros B, Kakkos S, De Maeseneer M, Nicolaides A. Chronic venous disease: from symptoms to microcirculation. International Angiology. 2019;38(3):211-218. https://doi.org/10.23736/s0392-9590.19.04116-6
Ruffini I, Belcaro G, Cesarone M, Dugall M. Efficacy of Topical Treatment with Aescin + Essential Phospholipids Gel in Venous Insufficiency and Hypertension. Angiology. 2004;55(6 suppl):19-21. https://doi.org/10.1177/000331970405500605
Cesarone M, Belcaro G, Ippolito E, Ricci A, Ruffini M, Dugall M. Microcirculatory Efficacy of Topical Treatment with Aescin + Essential Phospholipids Gel on Transcutaneous PO2 in Venous Insufficiency. Angiology. 2004;55(6 Suppl):7-10. https://doi.org/10.1177/000331970405500602
Ricci A, Ruffini I, Cesarone MR, Cornelli U, Corsi M, Belcaro G, Ippolito E, Dugall M. Variations in Plasma Free Radicals with Topical Aescin + Essential Phospholipids Gel in Venous Hypertension: New Clinical Data. Angiology. 2004;55(6 Suppl):11-14. https://doi.org/10.1177/000331970405500603
Belcaro G, Cesarone MR, Dugall M. Microcirculatory efficacy of topical treatment with aescin + essential phospholipids gel in venous insufficiency and hypertension: new clinical observations. Angiology. 2004;55(Suppl 1):1-5. https://doi.org/10.1177/000331970405500601
Bogachev VYu, Boldin BV, Turkin PYu. Sovremennaya terapiya khronicheskikh zabolevanij ven nizhnikh konechnostej: v fokuse — transdermal’nye flebotropnye preparaty. RMZh. 2018;6(2):61-65. (In Russ.).
Baranski K, Chudek J. Factors affecting patients’ self-management in chronic venous disorders: a single-center study. Patient Prefer Adherence. 2016;10:1623-1629. https://doi.org/10.2147/ppa.s110773